跳至主要内容
临床试验/NCT05976477
NCT05976477尚未招募不适用

Reduction Of Dietary Salt Intake To Control Systolic Blood Pressure In Hypertensive Older Patients: The Repress Randomized Controlled Trial

Mario Negri Institute for Pharmacological Research0 个研究点目标入组 266 人开始时间: 2023年10月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
266
主要终点
Change in systolic BP

研究概览

简要总结

REPRESS is an open label, pragmatic, multicenter, randomized controlled phase III trial with blinded endpoint with 1:1 (intervention to control arm) allocation ratio.

The REPRESS trial is aimed to determine the efficacy of an educational intervention aimed at reducing dietary salt intake in elderly people (60+) with moderate hypertension and exposed to polypharmacy (3+ drugs) in improving systolic BP control compared to an attention arm.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Double (Care Provider, Outcomes Assessor)

入排标准

年龄范围
60 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Community-dwelling patients aged ≥60 years;
  • Prescribed ≥3 drugs;
  • A) Systolic blood pressure ≥130 and ≤160 mmHg for patients prescribed stable antihypertensive therapy (at least 1 drug (ATC code: C02*, C03*, C07*, C08*, C09*)); B) Systolic blood pressure ≥140 and ≤160 mmHg for those patients not prescribed any antihypertensive drug;
  • Capable of feeding independently;
  • Own a smartphone;
  • Frequently consuming home-cooked meals (≥4 days during a week and ≥3 during the weekend per month);
  • Giving signed informed consent.

排除标准

  • Living in a nursing home or having applied for nursing home admission;
  • Being prescribed (adding, switching or changing dosage) an antihypertensive drug in the three months before enrollment;
  • Undergoing renal replacement therapy with dialysis or having renal impairment with estimated glomerular filtration rate (eGFR) <25 mL/min/1.73 m2 (assessed by CKD-EPI formula) [30] within previous six months or at the screening assessment;
  • Following a low-sodium dietary regimen;
  • Being unable or refusing to sign informed consent.

结局指标

主要结局

Change in systolic BP

时间窗: 6 months

The primary outcome will be the change in systolic BP defined as the difference from baseline to 12 weeks follow-up in the two study groups.

次要结局

  • Change in 24-hour urinary sodium excretion(6 and 12 months)
  • Change in adherence to the mediterranean diet(6 and 12 months)
  • Incidence of cardio- and cerebro-vascular events(12 months)

研究者

发起方
Mario Negri Institute for Pharmacological Research
申办方类型
Other
责任方
Principal Investigator
主要研究者

Carlotta Franchi

PRINCIPAL INVESTIGATOR

Mario Negri Institute for Pharmacological Research

相似试验